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Abstract
Background: Cinnamomum cassia bark is the outer skin of an evergreen tall tree belonging to the family
Lauraceae containing several active components such as essential oils (cinnamic aldehyde and cinnamyl aldehyde),
tannin, mucus and carbohydrate. They have various biological functions including anti-oxidant, anti-microbial, anti-
inflammation, anti-diabetic and anti-tumor activity. Previously, we have reported that anti-cancer effect of
cinnamon extracts is associated with modulation of angiogenesis and effector function of CD8+ T cells. In this
study, we further identified that anti-tumor effect of cinnamon extracts is also link with enhanced pro-apoptotic
activity by inhibiting the activities NFB and AP1 in mouse melanoma model.
Methods: Water soluble cinnamon extract was obtained and quality of cinnamon extract was evaluated by HPLC
(High Performance Liquid Chromatography) analysis. In this study, we tested anti-tumor activity and elucidated
action mechanism of cinnamon extract using various types of tumor cell lines including lymphoma, melanoma,
cervix cancer and colorectal cancer in vitro and in vivo mouse melanoma model.
Results: Cinnamon extract strongly inhibited tumor cell proliferation in vitro and induced active cell death of
tumor cells by up-regulating pro-apoptotic molecules while inhibiting NFB and AP1 activity and their target
genes such as Bcl-2, BcL-xL and survivin. Oral administration of cinnamon extract in melanoma transplantation
model significantly inhibited tumor growth with the same mechanism of action observed in vitro.
Conclusion: Our study suggests that anti-tumor effect of cinnamon extracts is directly linked with enhanced
pro-apoptotic activity and inhibition of NFB and AP1 activities and their target genes in vitro and in vivo mouse
melanoma model. Hence, further elucidation of active components of cinnamon extract could lead to
development of potent anti-tumor agent or complementary and alternative medicine for the treatment of diverse
cancers.
Background
Herbal medicines are plant-derived products which have
been used as traditional folk medicine and food addi-
tives. Recently their medicinal properties are under
extensive investigation and become a major part of com-
plementary and alternative medicines (CAMs). Their
potency for treating different diseases has been reported
including cancer, allergy and diabetes [1-4].
Cinnamomum cassia bark is the outer skin of an ever-
green tall tree belonging to the family Lauraceae. Its
extracts contain several active components such as
essential oils (cinnamic aldehyde and cinnamyl alde-
hyde), tannin, mucus and carbohydrates [5,6]. They have
various biological functions including anti-oxidant, anti-
microbial, anti-inflammation, anti-diabetic effects [7-12],
and anti-tumor activity [11,13]. However, for the devel-
opment of cinnamon as CAMs for cancer treatment,
further studies are necessary such as elucidation of
working mechanisms and characterization of active
compounds directly linked with anti-tumor activity.
Cancers are the most life-threatening health problems
in the world [14]. There have been many trials to treat
cancers through modulation of anti-tumor immune
response, apoptosis and anti-tumor proteins [15-18].
Tumor cells are generally resistant to apoptosis; hence
selective killing of tumor cells by promoting apoptosis
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pathway is an attractive and effective way for develop-
ment of anti-cancer agents. NFB and AP1 constitu-
tively active in many kinds of cancers and play critical
roles in tumor development and progression through
modulation of their target genes involved in angiogen-
esis, metastasis and cell survival [19-21].
Recently we have reported that anti-cancer effect of
cinnamon extracts is associated with modulation of
angiogenesis and effector function of CD8+ T cells [22].
In this study we further identified that anti-tumor effect
of cinnamon extracts is also linked with their enhanced
pro-apoptotic activity by inhibiting the activities of
NFB and AP1 in mouse melanoma model.
Methods
Animals
C57BL/6 mice (6~8 weeks, male) were purchased from
SLC (Japan) and maintained under specific pathogen-
free conditions in an animal facility at the Gwangju
Institute of Science and Technology (GIST). All of the
animal experiments were approved by the GIST Animal
Care and Use Committee.
Preparation of cinnamon extract
Dried Cinnamomum cassia bark (Hwajin Distribution
Co., Seoul, Korea) was pulverized and extracted for
three hours in a hot water extractor. The extract was
filtered and the supernatant was concentrated with a
rotary evaporator. The extract was then freeze dried
resulting in a powder extract. The powder extract was
suspended in sterilized distilled water at appropriate
concentrations. As we reported in our previous work
[22], HPLC analysis was performed by comparing the
levels of trans-cinnamic acid (Sigma, USA) and
cinnamic aldehyde (kindly provided by Dr. Ehren.,
Germany) as known standards makers for the quality
control of composition of cinnamon extract in each
experiment. Chromatography was carried out using 1%
acetic acid (H20)-MeOH (50: 50 v/v) at room tempera-
ture on a Phenomenex Luna 5u C18, 100 A pore size,
250 × 4.60 mm I.D. column. The flow rate of the mobile
phase was 2 ml/min. The amount of trans-cinnamic
acid and cinnamic aldehyde was about 2.9 (mg/g
extract) and 7.9 (mg/g extract) in each extract [22].
Cell lines
B16F10 and Clone M3 (mouse melanoma cell), Hela
(human cervical carcinoma cell) and Caco2 (human
epithelial colorectal adenocarcinoma cell) were obtained
from the Korean Cell Line Bank (Seoul National Univer-
sity, Korea) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (Hyclone Laboratories, Logan, USA),
100 U/ml penicillin (Sigma) and 100 μg/ml streptomycin
(Sigma). To check effects of cinnamon extract in normal
cells, primary mouse lymphocytes were isolated and
cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum,
L-glutamine, penicillin-streptomycin, nonessential
amino acids, sodium pyruvate, vitamins, HEPES and
2-mercaptoethanol.
Cell viability analysis
Cell viability and proliferation were determined with
EZ-Cytox Cell Viability Assay Kit (Daeil Labservice,
Korea) based on the cleavage of the tetrazolium salt to
water-soluble formazan by succinate-tetrazolium reduc-
tase. Briefly, cells were treated with cinnamon extract
(0.5 mg/ml) or Doxorubicin (Sigma) for indicated time
points in 6 well plates. After treatment, cells were trans-
ferred into 96 well plates in 100 μl of medium and incu-
bated with 10 μl of Ez-CyTox solution for 5 hours in
the 37°C incubator. Then absorbance were measured
using the Easy Reader EAR 400 (SLT-Lab Instruments,
Austria) at 420~480nm. Data was presented by relative
growth inhibition to PBS treated cells.
Cell cycle analysis
The effect on cell division by cinnamon treatment was
determined by assessing cellular DNA content using
propidium iodide (PI) staining [23]. Briefly, cells were
treated with 0.5 mg/ml of cinnamon extract for indi-
cated time periods and then each sample was harvested
and fixed in 70% ethanol for 10 hours. After fixation,
cells were washed with PBS, treated with 0.5 μg/ml of
DNase-free RNase (Sigma) for 20 mins at room tem-
perature and stained with 100 μg/ml of PI in 0.1 M
sodium citrate buffer (pH 7.4) for 30 mins at 4°C. Flow
cytometric analysis (FACS) was performed with EPICS
XL Cytometer (Beckman Coulter) and cell cycle distri-
bution was determined with Expo32 program (Beckman
Coulter)
Apoptosis analysis
Cells (1 × 106) were treated with cinnamon extract
(0.5 mg/ml) for indicated time periods and then resus-
pended in 1ml of 1× Annexin V binding buffer (BD
bioscience). After incubating for 15 mins with 5 μl of
Annexin V-PE and 7-ADD, at 25°C in the dark, 400 μl
of 1× binding buffer was added to each tube and imme-
diately analyzed by FACS. Cells stained with isotype
matched normal IgG used as a control and showed less
than 0.2% positive population (data not shown).
Luciferase assay
B16F10 cells were transfected with AP1- or NFB-
dependent reporter construct that contains repeated
copies of NFB or AP1 response elements. After
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18 hours culture in complete media, cells were stimulated
with PMA (phorbol 12-myristate 13-acetate) and iono-
mycin (P+I) for 4 hours in the presence or absence sev-
eral dose of cinnamon extract from 0.1 mg/ml to 0.5 mg/
ml. Luciferase activity measured by dual luciferase assay
system (Promega) is expressed relative to expression of
the cotransfected Renilla luciferase promoter (phRL-null;
Promega) to control for transfection efficiency.
RNA isolation, cDNA synthesis, quantitative RT-PCR and
standard RT-PCR
Total RNA was prepared using TRI Reagent (Molecular
Research Center) according to the manufacturer’s proto-
col. For reverse transcription, cDNA was generated using
1 μg of total RNA, oligo (dT) primer (Promega) and
Improm-II Reverse Transcriptase (Promega) in a total
volume of 20 μl. One μl of cDNA was amplified using the









and 5′-GCCTCGCGGTAATCATTTGC-3′); Bad (5′-AA
GTCCGATCCCGGAATCC-3′ and 5′-GCTCA CTCGGC
TCAAACTCT-3′) and 5′-GGTATGCACCCAGAGTGAT
GC-3′), and Survivin (5′-CTACCGAGAACGAGCCT-
GATT-3′ and 5′- AGCCTTCCAATTCCTTAAAGCAG-3′).
Preparation of nuclear extracts
Cell lines or cells isolated from tumor tissues were
washed twice with ice cold PBS and incubated in 1ml of
lysis buffer (10 mM Tris/HCl, 3 mM CaCl2, 2 mM
MgCl2) containing a protease inhibitor cocktail (Roche)
for 10 mins on ice. Then the cells were vortexed gently
and incubated in 1ml of NP-40 buffer (10 mM Tris/HCl,
3 mM CaCl2, 2 mM MgCl2, 1% NP-40) for 5 mins at 4°C,
and the suspension was centrifuged at 3000 rpm for 10
mins at 4°C. Nuclei was washed with 1ml of Buffer A (20
mM Hepes-KOH, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, 0.5 mM PMSF), and 100 μl of Buffer C (20 mM
Hepes-KOH, 25% Glycerol, 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 5 mM DTT, 0.5 mM PMSF, 1%
Triton X-100) was added to the pellet and vortexed vig-
orously at 4°C for 10 mins. Nuclear debris was removed
by centrifugation at 13000 g for 5 mins. Protein concen-
trations were determined by the Bradford Assay (Bio-
Rad). The nuclear extract was confirmed by immunoblot-
ting with anti-Lamin B and anti-Tubulin beta. For single
cell suspension of tumor tissues, tumor tissues from each
group was homogeized with homogenizer (Fluko).
Immunoblotting
Proteins were resolved by 10% (for NFB and AP1) or
15% (for caspase-3, Bcl2, Bcl-xL, Bad, Bax, Bak, Bim and
Sruvivin) SDS-PAGE gels, transferred onto a PVDF
membrane (Bio-RAD) and subjected to Western blot
analysis using anti-NFB (Abcam), anti-pc-JUN (Santa-
Cruz), anti-caspases-3 (Abcam), anti-Bcl-2 (Abcam),
anti-Bcl-xL (Cell signaling), anti-Survivin (Cell signal-
ing), anti-Bad (Abcam), anti-Bax (Abcam), anti-Bak
(Abcam), anti-Bim (Abcam) and peroxidase-conjugated
secondary antibodies (DAKO). Proteins were visualized
with a chemiluminescence kit (Amersham Bioscience).
The levels of Tubulin (anti-tubulin; Santa Cruz), beta-
actin (anti-beta-actin; Abcam) and Lamin B (anti-lamin
B; SantaCruz) detected by relevant antibodies were
monitored as a loading control.
Melanoma induction and anti-tumor assay
Mouse melanoma B16F10 (1 × 106 cells/0.1ml) cells
were injected subcutaneously (s.c) into the flanks of
C57BL/6 mice (6 weeks old male). One week after the
injection, mice were divided into two groups (10 mice/
each group) and orally treated with either 10 mg/dose
(400 μg/g mouse weight) of cinnamon extract in 100 μl
of PBS or same volume of PBS alone as a sham control
for 30 days. During the treatment period, the tumor size
was measured with vernier calipers every 2 days, and
tumor volumes were calculated using the standard for-
mula: width2 × length × 0.52. Mice were sacrificed for
further analysis after 30 days of treatment.
DNA fragmentation assay
Genomic DNA isolation was performed with gDNA puri-
fication kit (Solgent, Korea). Briefly, mouse tumor tissues
from the differentially treated group were collected,
pooled, and 5 mg of tumor tissues from each group were
transferred. They were dissolved in 300ml of cell lysis buf-
fer with 25 mg of proteinase K for 4 hours at 55°C, and
then mixed with 100ml of protein precipitation solution.
Then solution was centrifugated at 14000 rpm for 3 mins.
After centrifugation, DNAs was precipitated, washed with
isopropanol and 70% ethanol. DNA pellets were dissolved
in 100 μl of DNA hydration solution. Finally, fragmented
DNAs (10 ml) were visualized in 2% agarose gels.
Nuclear staining
Cells seeded on the glass in 12 well plate were incubated
with cinnamon extract for 72 hours, washed with PBS
and fixed with 4% paraformaldehyde for 15 mins at RT.
Fixed cells were incubated in PBS (pH 7.4) containing
200mg of DNase-free RNase (Sigma) for 30 mins at
37°C and stained with 2 mg/ml of Hoechst for 10 mins
at 37°C. Nuclear morphology of the cells was observed
under fluorescence microscope.
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Statistical analysis
A two-tailed Student’s t-test was employed where P <
0.05 was considered to be statistically significant (*p <
0.05, **p < 0.005, and ***p < 0.001).
Results
Cinnamon extract inhibits tumor cell growth in vitro
To define the optimal concentration at which cinnamon
extract does not induce cell damage, the cytotoxicity
test was performed in melanoma cell lines. As we
reported previously, treatment of cinnamon extract up
to 0.5 mg/ml did not induce growth inhibition and mor-
phological changes till 24 hrs [22]. However, tumor cells
showed significant decrease in cell proliferation after 48
hrs treatment of cinnamon extract (Figure 1). They
showed condensed, shrank and aggregated shapes.
Seventy two hours after treatment of cinnamon extract,
most of the cells became floating with aggregated form
detached from the plates (Figure 1A). To confirm the
effects of cinnamon treatment on tumor cell survival,
proliferation and cell viability were measured (Figure
1B). In the presence of cinnamon extract, the rate of
tumor cell growth was significantly inhibited (Figure
1B). To validate our experimental system, we used EL4
T lymphoma cell line as a positive control that showed
cell cycle arrest and growth inhibition upon treatment
of polyphenolic compound from cinnamon [24]. We
checked whether cinnamon extract also induced growth
inhibition of normal cells. Primary mouse lymphocytes
were treated with same concentration (0.5 mg/ml) of
cinnamon extracts and cell viability was measured
(Additional file 1, Figure S1A). Interestingly, treatment
of cinnamon extract (0.5 mg/ml) did not induce any
growth inhibition in primary mouse lymphocyte.
Treatment of cinnamon extract induces active cell death
of melanoma cells in vitro
Growth inhibition of tumor cells by the treatment of
cinnamon extract could be mediated by several mechan-
isms. A recent report showed that phenolic compound
of cinnamon bark induces cell cycle arrest in hematolo-
gic cell lines [11]. Hence, we first tested whether cinna-
mon extract induced cell cycle arrest in mouse
melanoma cell line, B16F10 cells. Treatment of cinna-
mon extract slightly induced cell cycle arrest at S phage
(Additional file 2, Table S1). We further tested whether
growth inhibition by treatment of cinnamon is related
with induction of apoptosis (Figure 2). Although cinna-
mon treatment did not induce growth inhibition and
morphological chance within 24 hrs [22], a gradual
increase in early apoptotic population (Annexin V+) was
observed (Figure 2A and 2B; 12 and 24 hrs). Further
enhancement of apoptotic population in late stage
(Annexin V+/7-ADD+) was observed in a time-depen-
dent manner (Figure 2A). To further confirm these
results, we checked whether treatment of cinnamon
extract induces apoptosis in another type of cancer cell
line, Caco2 (human epithelial colorectal adenocarcinoma
Figure 1 Treatment of cinnamon extract inhibits the growth of various cancer cells. Cinnamon (0.5 mg/ml) was treated for 0, 48 and 72
hrs to cancer cell lines (Hela; cervical cancer, Caco2; colon cancer, Clone M3; melanoma and B16F10; melanoma). After treatment of cinnamon
extract, (A) morphological changes of each cancer cell lines were monitored by microscopic observation. (B) Proliferation and viability of cancer
cells were measured by cell viability assay at the indicated time points. Error bars indicated SD. Data are representative of three independent
experiments.
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cell). Like in B16F10 melanoma cells, treatment of cin-
namon extract induced apoptosis in Caco2 as well
(Additional file 3, Figure S2). From these experiments,
we could infer that cinnamon extract induced apoptosis
in cancer cells rather than showing simple cytotoxic
effects. Next, we tested whether cinnamon extract
induced apoptosis is affected by changes in the expres-
sion level of apoptosis related genes [25]. Indeed, treat-
ment of cinnamon extract significantly increased mRNA
expression (Figure 2C) and protein (Figure 2D) levels of
pro-apoptotic genes such as Bad, Bim, Bax and Bak.
Cinnamon extract inhibits the melanoma growth by
inhibiting NFB and AP1
NFB and AP1 have critical roles in tumor cell survival.
They regulate the gene expression program of apoptosis
and cell cycle [21,26]. Hence, we checked whether a
pro-apoptotic activity of cinnamon extract is linked with
changes in the levels and activities of NFB and AP1.
Interestingly, cinnamon extract decreased the amount of
NFB and AP1 proteins in total cell lysates (left panel
in Figure 3A) as well as in nucleus extracts (right panel
in Figure 3A). To further test whether cinnamon extract
also affected on NFB and AP1 activities, luciferase-
based reporter assay was performed. B16F10 cells were
stimulated with PMA + ionomycin (P+I) to activate
NFB and AP1 in the absence or presence of cinnamon
extract. Indeed, treatments of cinnamon extract (CE)
significantly down-regulated NFB and AP1 activities in
a dose dependent manner (Figure 3B and 3C). Next, we
checked whether down-regulation of NFB and AP1
levels and their activities by cinnamon treatment could
also affect expression level of their target genes related
with apoptosis and cell survival such as Bcl-2, BcL-xL
and survivin [21,27]. Indeed, cinnamon extract signifi-
cantly down-regulated the expression (Figure 3D) and
protein (Figure 3E) levels of Bcl-2, BcL-xL and survivin
in a time dependent manner. These results suggest that
reduction in the levels and activities of NFB and AP1
by cinnamon extract down-regulated their target mole-
cules involved in tumor cell survival.
Oral administration of cinnamon extract significantly
inhibits melanoma progression in vivo
To further confirm the anti-tumor effect of cinnamon
extract in vivo, we orally administrated cinnamon
extract to a mouse melanoma model. Ten days after
subcutaneous transplantation of melanoma cells
(B16F10), mice were divided into two groups. Mice in
each group were daily treated with cinnamon extract
(CE; 400 μg/g mouse weight) or same volume of PBS as
a sham control group (Cont) for 30 days by oral-admin-
istration with catheter (Figure 4). The dose of cinnamon
extract in oral administration was based on our previous
work [22] that did show any cytotoxic effect in normal
mice. To test anti-tumor effects of cinnamon extract,
Figure 2 Cinnamon extract treatment induces active cell death in melanoma cells. At the indicated time periods after treatment of
cinnamon extract, cells were stained with Annexin V and 7-ADD. Double positive (Annexin V+ and 7-ADD+) (A) or Annexin V+ positive (B)
populations were analyzed by FACS. Gene expression (C) and protein (D) level of pro-apoptotic molecules such as Bad, Bim, Bax and Bak were
measured by quantitative real-time PCR or immunoblotting, respectively. Error bars indicated SD. One (*), two (**) or three asterisks (***) indicate
p < 0.05, p < 0.005 or p < 0.001, respectively. Data are representative of three independent experiments.
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tumor volume was measured throughout the treatment
period (Figure 4B). Oral administration of cinnamon
extract significantly reduced tumor size compared with
control group (Figure 4A and 4B). Consistent with
tumor volume, cinnamon treated group showed signifi-
cant decrease of tumor weight compared with control
groups (cinnamon group; 6.2 g vs. control group; 12.1 g)
(Figure 4C). A reduction in tumor size by administration
of cinnamon extract significantly increased a survivor
rate compared with control group (Figure 4D). These
data suggests that oral administration of cinnamon
extract has potent anti-tumor activity in vivo.
Anti-tumor effect of cinnamon extract is linked to the
reduced levels of NFB and AP1 in vivo melanoma model
To get the detail action mechanisms of cinnamon
in vivo, we tried to investigate whether anti-tumoral
effects of cinnamon in vivo melanoma model is also
mediated by the similar mechanisms of in vitro system
such as active tumor cell death and inhibition of NFB
and AP1 activities (Figure 1 and Figure 2). Apoptosis
assay was performed with the cells obtained from the
tumor tissues of each treatment group, cinnamon
extract (CE) and PBS (cont). First, DNA fragmentation
assay was performed [28]. Genomic DNAs purified from
each treatment group were separated by gel
electrophoresis to compare DNA laddering generated by
apoptosis. As shown in Figure 5A, DNA isolated from
cinnamon extract treated mice (CE) showed a significant
increase in DNA fragmentation levels compared with
PBS group (Cont) (Figure 5A). Next, we checked the
protein levels of caspase-3. Cinnamon extract treatment
did not alter the levels of inactive pro-caspase 3 (Figure
5B). Interestingly, however, cinnamon extract treatment
significantly increased the level of active caspases-3
compared with the control group (Figure 5B). In addi-
tion, the pro-apoptotic effect of cinnamon extract in
tumor tissue was further confirmed by tissue staining
with Hoechst dye under microscopic observation. Com-
pared with the PBS treated group, tumor tissue sections
isolated from cinnamon treated group (CE) showed
enhancement of apoptotic population showing con-
densed chromatin at the nuclear membrane (crescent
formation), dissolution of the nuclear membrane, and
apoptotic nucleus surrounded by a rim of cytoplasm
and plasma membrane [29] (Figure 5C and Additional
file 4, Figure S3). In agreement with in vitro data, these
data suggest that in vivo anti-tumoral effect of cinna-
mon extract is also linked with significant increment of
apoptosis in the melanoma tissues. Next, we examined
whether in vivo anti-tumoral effect of cinnamon extract
is also directly associated with the down-regulation of
Figure 3 Cinnamon extract treatment down-regulates the levels of NFB and AP1 and their target genes. (A) After treatment of
cinnamon extract for indicated time periods, the levels of NFB and AP1 in total cell lysates (left) and nucleus extracts (right) were compared by
immunoblotting. The effect of cinnamon extract on the activity NFB (B) and AP1 (C) was measured by reporter assay. B16F10 cells were
transfected with AP1- or NFB-dependent reporter construct and then stimulated with PMA and ionomycin (P+I) for 4 hours in the absence or
presence of cinnamon extract (CE). Gene expression (D) and protein (E) levels of anti-apoptotic genes were measured by quantitative real-time
PCR or immunoblotting, respectively. Data are representative of three independent experiments with similar results. One (*), two (**) or three
asterisks (***) indicate p < 0.05, p < 0.005 or p < 0.001, respectively.
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NFB and AP1 levels. Indeed, tumor tissues isolated
from cinnamon extract treated group (CE) showed a sig-
nificant reduction in NFB and AP1 levels compared
with PBS treated control group (Cont) (Figure 5D). We
also tested whether down-regulation NFB and AP1
leads to a decrease in the levels of their target genes
such as Bcl-2, BcL-xL and survivin. The mRNA expres-
sion (Figure 5E) and protein (Figure 5F) levels of these
target molecules were analyzed from the tumor tissues
of each treatment groups. Indeed, tumor tissues from
cinnamon extract treated mice showed a significant
decrease in the levels of Bcl-2 and BcL-xL compared
with control group (Figure 5E and 5F). These data indi-
cate that anti-tumoral effects of cinnamon extract is
mediated by induction of tumor apoptosis through the
inhibition of NFB and AP1 levels.
Discussion
Cinnamon is a herbal plant that has been used for
various purposes as forms of dietary intake, oriental
Figure 4 Oral administration of cinnamon extract inhibits melanoma growth in vivo. Ten days after melanoma transplantation, cinnamon
extract (CE; 400 μg/g mouse weight) or PBS (Cont) was orally administrated every two days for 20 days. (A) Photographs of representative
tumors from each group at day 14 and 30. During the treatment period, the tumor volumes (B) and tumors weights (C) and survivor rate (D) in
each group were daily measured. Data are representative of three independent experiments (10 mice/each group). One (*) or two (**) asterisks
indicates p < 0.05 or p < 0.005, respectively. Data are representative of three individual experiments.
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medicine and CAMs [30]. However, it is still unclear
about the exact action mechanisms of cinnamon and its
active components related with diverse biological func-
tion. Although various beneficial effects of cinnamon
extract have been reported, most studies were per-
formed in vitro culture system without elucidation of
mechanism of action in vivo.
In our previous work [22], we have shown that anti-
tumoral effects of cinnamon extract in mouse melanoma
is mediated by modulation of angiogenesis and cytotoxic
activity of CD8+ T cells. In the present study, we further
demonstrated that anti-tumoral effects of cinnamon
extract are also linked with the induction of apoptosis in
a cancer specific manner. In addition, treatment of cin-
namon extract reduced the levels and activities of NFB
and AP1 and their target genes such as Bcl-2 and Bcl-
xL. These findings strongly suggest that potent anti-
tumoral effects of cinnamon extract are mediated by
multiple action mechanisms.
Active induction of apoptosis in a cancer specific
manner is an attractive way to cure many types of can-
cers [31,32]. Cancers have various strategies to escape
from the recognition and elimination by the surveillance
of host immune system. These include altered expres-
sion of genes and proteins involved in cell survival,
death and transformation [33]. Among them, one of
common survival strategy of cancer cells is to escape
from apoptosis by deregulation of apoptotic genes [32]
or hyper-activation of anti-apoptotic genes [34]. There-
fore, cancer specific induction of apoptosis is thought to
be a good strategy for cancer treatment. In this study,
we demonstrated that treatment of cinnamon extract
suppressed melanoma progression in vivo (Figure 4 and
5) and inhibition of tumor cell growth in vitro (Figure 1
and Figure 2) through apoptosis induction. Compared
with known anti-cancer drugs (for example, Doxorubi-
cin) [35], potential benefit of cinnamon extract as a
complementary and alternative medicine may contribute
Figure 5 Cinnamon extract treatment induces tumor apoptosis by decreasing the levels of NFB and AP1 and their target genes. (A)
Genomic DNA was isolated from tumor tissues from each treatment group and DNA fragmentation was confirmed by staining with ethidium
bromide in 2% agarose gel. (B) The protein levels of pro-caspase and active caspases 3 in tumor tissues from each group were determined by
immunoblotting. (C) To check the structural changes of nucleus, tumor tissues from each group were sectioned and then stained with Hoechst.
Round areas and arrows indicate apoptotic cells (bigger size of this picture was included in Additional file 4, Figure S3). (D) The levels of NFB
and AP1 in tumor tissues from each group were compared by immunoblotting between the treatment groups. The gene expression (E) and
protein (F) level of Bcl-2, BcL-xL and survivin in tumor tissues were measured by quantitative real-time PCR or immunoblotting, respectively. Two
(**) asterisk indicates p < 0.005. Not significant (NS). Data are representative of three individual experiments with similar results.
Kwon et al. BMC Cancer 2010, 10:392
http://www.biomedcentral.com/1471-2407/10/392
Page 8 of 10
to its less cytotoxicity in normal cells (Additional file 1,
Figure S1B). To compare cytotoxicity of cinnamon
extract with anti-cancer drug (e.g, Doxorubicin), firstly
we titrated and decided an optimal concentration of cin-
namon extract (CE; 0.5 mg/ml) and Doxorubicin (Dox;
5 μM) [35,36] that does not induce apoptosis in normal
cells. Cinnamon extract and Doxorubicin induced com-
parable level of apoptosis induction in melanoma cells
(CE; 60% and Dox; 70%, respectively) (Additional file 1,
Figure S1B). Interestingly, however, compared with cin-
namon extract, Doxorubicin showed much higher toxic
effect in normal cells (primary mouse lymphocyte)
(Additional file 1, Figure S1B). Doxorubicin treatment
induced significantly higher levels apoptosis (up to 50%)
of normal lymphocyte while cinnamon extract induced
marginal effect (about 10%) (Additional file 1, Figure
S1B). These results suggest a beneficial effect of cinna-
mon extract with less cytotoxicity than conventional
anti-cancer drug in normal cells while maintains its
anti-tumor effect. However, further studies are needed
to elucidate mechanism of action and core active com-
pounds of cinnamon extract to induce cancer cell apop-
tosis without affecting normal cells.
NFB and AP1 play pivotal roles in tumorigenesis
[20,21,26]. Interestingly, treatment of cinnamon extract
strongly down-regulated the levels and activities of
NFB and AP1 both in melanoma cell line (Figure 3)
and in mouse melanoma (Figure 5). NFB is a major
regulator of cell proliferation and cell survival. It inhibits
apoptosis while stimulating cell proliferation, metastasis,
angiogenesis and inflammation [26]. Anti-apoptotic
activities of NFB is generally mediated by activation of
set of genes related with cell survival [27]. Together
with NFB, AP1 has also critical roles in tumorigenesis.
It stimulates the expression of anti-apoptotic genes,
invasive tumor growth, metastasis and angiogenesis [21].
Bcl-2, BcL-xL and survivin are key anti-apoptotic con-
ductors and are target genes of NFB and AP1 [25].
Treatment of cinnamon extract significantly down-regu-
lated their mRNA expression and protein levels in
tumor cell line (Figure 3D and 3E) and melanoma tissue
(Figure 5E and 5F) as well. These results suggest that
anti-tumor effect of cinnamon extract is linked with the
inhibition of NFB and AP1 and their target genes
involved in tumor cell survival and proliferation. In this
study, we demonstrated the anti-tumor effect of cinna-
mon extract in vivo melanoma model. Although cinna-
mon extracts increased apoptosis in various cancer cell
lines such as lymphoma, cervical cancer and colorectal
cancer (Figure 1), in vivo animal studies are necessary to
test whether cinnamon extracts have also anti-tumor
effects in other types of cancers. In summary, anti-
tumor effects of cinnamon extract appear to be
mediated by multiple mechanisms. These include inhibi-
tion of angiogenesis, potentiating CD8+ T cell cytotoxi-
city [22] and apoptosis induction in tumor cells.
Collectively, our work suggests the potent anti-tumor
effect of cinnamon extract.
Conclusions
Cinnamon extract potently inhibited various tumor cell
growths in vitro and suppressed in vivo melanoma pro-
gression. Anti-cancer effect of cinnamon extract is
mediated by apoptosis induction and blockade of NFB
and AP1. Hence, cinnamon extract could lead to devel-
opment of potent anti-tumor agent or complementary
and alternative medicines for the treatment of diverse
cancers.
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Additional file 1: Figure S1. Treatment of cinnamon extract induces
cancer cell-specific apoptosis. Tumor specific apoptotic effects of
cinnamon by comparing induction of apoptotic population between
normal mouse lymphocytes and B16F10 melanoma cells upon treatment
of cinnamon extract or Doxorubicin.
Additional file 2: Table S1. Cinnamon treatment induced cell cycle
alteration in tumor cells. After treatment of cinnamon extract for
indicated times (0, 48 and 72 hrs), cell cycle analysis of each sample was
performed by propidium iodide staining.
Additional file 3: Figure S2. Treatment of cinnamon induces
apoptosis in adenocarcinoma cell. Effects of cinnamon extract
treatment into Caco2 cells (human epithelial colorectal adenocarcinoma
cell line) by checking alteration of apoptotic population.
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induced cell death in tumor tissues. In vivo tumor specific apoptosis
by cinnamon treatment was confirmed by checking the structural
changes of nucleus in tumor tissue.
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